Clinical Study on the Treatment of Acute Coronary Syndrome in Remission with Shexiang Baoxin Pill Combined With Metoprolol Succinate

We attempt to investigate the clinical efficacy and safety of Shexiang Baoxin pill combined with metoprolol succinate in acute coronary syndrome at remission stage patients. We randomly selected 72 patients in remission stage of acute coronary syndrome in our cardiology department from March 2021 to December 2021, then divided them into observation group (36 cases with Shexiang Baoxin pill combined with metoprolol succinate treatment) and control group (36 cases with metoprolol succinate treatment). Besides, both groups treated with standardized Western medicine, anti-platelet, lipid-lowering drugs, etc. Compared both groups on the clinical effective rate, cardiac function indexes changes and plasma endothelial function indexes (angiotensin II, endothelin-1 and nitric oxide) changes before and after treatment. Left ventricular end-diastolic dimension and left ventricular end-systolic dimension value of observation group decreased remarkably higher than control group after treatment (p<0.01); observation group possessed remarkably higher value than control group (p<0.01). After 1 mo treatment, in serum, angiotensin II and endothelin-1 concentration of observation group decreased more than control group (p<0.05), but nitric oxide concentration in serum increased more than control group (p<0.05). The total effective rate of observation group was 88.9 %, it was remarkably higher than control group (55.5 %) (p<0.05). The incidence of cardiovascular events in observation group (8.33 %) was remarkably lower than control group (13.89 %) (p<0.05). Shexiang Baoxin pill combined with metoprolol succinate can obviously improve the acute coronary syndrome remission patients' angina symptoms, improve heart function, and reduce the serum angiotensin II and endothelin-1, at the same time increase the nitric oxide concentration level, effectively reduce the incidence of cardiovascular events, can provide clinical guidance value for effective treatment in acute coronary syndrome remission patients.